CN
Therapeutic Areas
Atara Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EBVALLO™ (tabelecleucel) | EBV+ Post-Transplant Lymphoproliferative Disease (PTLD) | Approved |
| ATA3219 | B-Cell Non-Hodgkin Lymphoma (NHL) | Phase 1 |
| Drug | Indication | Phase |
|---|---|---|
| EBVALLO™ (tabelecleucel) | EBV+ Post-Transplant Lymphoproliferative Disease (PTLD) | Approved |
| ATA3219 | B-Cell Non-Hodgkin Lymphoma (NHL) | Phase 1 |